Dextenza sustained-release dexamethasone: Phase III data

Top-line data from a double-blind, U.S. Phase III trial in 86 patients with allergic conjunctivitis showed that 0.4 mg Dextenza intracanalicular depot given 48-72

Read the full 244 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE